Endocannabinoids

References:

1. Mechoulam, R. & Ben-Shabat, S. From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: the ongoing story of cannabis. Nat Prod Rep 16, 131-143 (1999).

2. Salzet, M. & Stefano, G. B. The endocannabinoid system in invertebrates. Prostaglandins Leukot Essent Fatty Acids 66, 353-361 (2002).

3. McPartland, J. M., Matias, I., Di Marzo, V. & Glass, M. Evolutionary origins of the endocannabinoid system. Gene 370, 64-74 (2006).

4. Reggio, P. H. Endocannabinoid structure-activity relationships for interaction at thecannabinoid receptors. Prostaglandins Leukot Essent Fatty Acids 66, 143-160 (2002).

5. Mechoulam, R., Braun, P. & Gaoni, Y. A stereospecific synthesis of (-)-delta 1- and (-)-delta 1(6)-tetrahydrocannabinols. J. Am. Chem. Soc. 89, 4552-4554 (1967).

6. Mechoulam, R. & Gaoni, Y. The absolute configuration of delta-1-tetrahydrocannabinol, the major active constituent of hashish. Tetrahedron Lett 12, 1109-1111 (1967).

7. Devane, W. A. et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949 (1992).

8. Mechoulam, R. et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50, 83-90 (1995).

9. Smith, W. L. Nutritionally essential fatty acids and biologically indispensable cyclooxygenases. Trends Biochem. Sci. 33, 27-37 (2008).

10. Di Marzo, V., Bifulco, M. & De Petrocellis, L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3, 771-784 (2004).

11. Fezza, F., Dillwith, J. W., Bisogno, T., Tucker, J. S. & Di. Endocannabinoids and related fatty acid amides, and their regulation, in the salivary glands of the lone star tick. Biochim. Biophys. Acta 1633, 61-67 (2003).

12. Maccarrone, M., Pauselli, R., Di Rienzo, M. & Finazzi-Agro, A. Binding,degradation and apoptotic activity of stearoylethanolamide in rat C6 glioma cells. Biochem. J. 366, 137-144 (2002).

13. Walker, J. M. et al. Targeted lipidomics: fatty acid amides and pain modulation. Prostaglandins Other Lipid Mediat 77, 35-45 (2005).

14. O’Sullivan, S. E., Kendall, D. A. & Randall, M. D. Vascular effects of delta 9-tetrahydrocannabinol (THC), anandamide and N-arachidonoyldopamine (NADA) in the rat isolated aorta. Eur. J. Pharmacol. 507, 211-221 (2005).

15. Sancho, R. et al. Immunosuppressive activity of endovanilloids: N-arachidonoyldopamine inhibits activation of the NF-kappa B, NFAT, and activator protein 1 signaling pathways. J. Immunol. 172, 2341-2351 (2004).

16. Chu, C. J. et al. N-oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia. J. Biol. Chem. 278, 13633-13639 (2003).

17. Walker, J. M., Krey, J. F., Chu, C. J. & Huang, S. M. Endocannabinoids and related fatty acid derivatives in pain modulation. Chem Phys Lipids 121, 159-172 (2002).

18. Hanus, L., Gopher, A., Almog, S. & Mechoulam, R. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J. Med. Chem. 36, 3032-3034 (1993).

19. Hanus, L. et al. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. U S A 98, 3662-3665 (2001).

20. Alexander, S. P. & Kendall, D. A. The complications of promiscuity: endocannabinoid action and metabolism. Br. J. Pharmacol. (2007).

21. Mechoulam, R., Fride, E. & Di Marzo, V. Endocannabinoids. Eur. J. Pharmacol. 359, 1-18 (1998).

22. Rock, E. M., Limebeer, C. L., Mechoulam, R., Piomelli, D. & Parker, L. A. The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat. Psychopharmacology (Berl) (2007).

23. Naidu, P. S. et al. Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology (Berl) S (2007).

24. Bortolato, M. et al. Antidepressant-like Activity of the Fatty Acid Amide Hydrolase Inhibitor URB597 in a Rat Model of Chronic Mild Stress. Biol Psychiatry (2007).

25. Hillard, C. J. et al. Inhibition of 2-arachidonoylglycerol catabolism modulates vasoconstriction of rat middle cerebral artery by the thromboxane mimetic, U- 46619. Br. J. Pharmacol. (2007).

26. Okamoto, Y., Wang, J., Morishita, J. & Ueda, N. Biosynthetic Pathways of the Endocannabinoid Anandamide. Chem Biodivers 4, 1842-1857 (2007).

27. Di Marzo, V. et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372, 686-691 (1994).

28. Piomelli, D., Giuffrida, A., Calignano, A. & Rodriguez de Fonseca, F. Theendocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci 21, 218-224 (2000).

29. Simon, G. M. & Cravatt, B. F. Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho-N-acyl ethanolamine precursors in mouse brain. J. Biol. Chem. (2008).

30. Rouzer, C. A. & Marnett, L. J. Non-redundant functions of cyclooxygenases: Oxygenation of endocannabinoids. J. Biol. Chem. (2008).

31. Woodward, D. F. et al. Identification of an antagonist that selectively blocks the activity of prostamides (prostaglandin-ethanolamides) in the feline iris. Br. J. Pharmacol. 150, 342-352 (2007).

32. Burk, R. M. & Woodward, D. F. A historical perspective and recent advances in prostamide research and therapeutics. Curr Opin Drug Discov Devel 10, 413-421 (2007).

33. Grosser, T., Fries, S. & FitzGerald, G. A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest. 116, 4-15 (2006).

34. Melamede, R. Harm reduction–the cannabis paradox. Harm Reduct J 2, 17 (2005).

35. Herkenham, M. et al. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. U S A 87, 1932-1936 (1990).

36. Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C. & Bonner, T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564 (1990).

37. Munro, S., Thomas, K. L. & Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65 (1993).

38. Baker, D., Pryce, G., Davies, W. L. & Hiley, C. R. In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci 27, 1-4 (2006).

39. Ryberg, E. et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. (2007).

40. Wu, D. F. et al. Role of receptor internalization in the agonist-induced desensitization of cannabinoid type 1 receptors. J. Neurochem. 104, 1132-1143 (2008).

41. Di Marzo, V. et al. Interactions between synthetic vanilloids and the endogenous cannabinoid system. FEBS Lett. 436, 449-454 (1998).

42. Starowicz, K., Nigam, S. & Di Marzo, V. Biochemistry and pharmacology of endovanilloids. Pharmacol Ther S (2007).

43. Starowicz, K., Cristino, L. & Di Marzo, V. TRPV1 receptors in the central nervous system: potential for previously unforeseen therapeutic applications. Curr Pharm Des 14, 42-54 (2008).

44. Maccarrone, M. et al. Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat. Neurosci. 11, 152-159 (2008).

45. Zhang, L. L. et al. Activation of transient receptor potential vanilloid type-1 channel prevents adipogenesis and obesity. Circ. Res. 100, 1063-1070 (2007).

46. Sawada, Y., Hosokawa, H., Hori, A., Matsumura, K. & Kobayashi, S. Cold sensitivity of recombinant TRPA1 channels. Brain Res. 1160, 39-46 (2007).

47. Akopian, A. N., Ruparel, N. B., Patwardhan, A. & Hargreaves, K. M. Cannabinoids desensitize capsaicin and mustard oil responses in sensory neurons via TRPA1 activation. J. Neurosci. 28, 1064-1075 (2008).

48. Sulcova, E., Mechoulam, R. & Fride, E. Biphasic effects of anandamide. Pharmacol Biochem Behav 59, 347-352 (1998).

49. Luquet, S. et al. Roles of peroxisome proliferator-activated receptor delta (PPARdelta) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome. Biochimie 86, 833-837 (2004).

50. Medina-Gomez, G., Gray, S. & Vidal-Puig, A. Adipogenesis and lipotoxicity: role of peroxisome proliferator-activated receptor gamma (PPARgamma) and PPARgammacoactivator-1 (PGC1). Public Health Nutr 10, 1132-1137 (2007).

51. Sun, Y., Alexander, S. P., Kendall, D. A. & Bennett, A. J. Cannabinoids and PPARalpha signalling. Biochem Soc Trans 34, 1095-1097 (2006).

52. Ghosh, M. et al. COX-2 suppresses tissue factor expression via endocannabinoiddirected PPAR{delta} activation. J. Exp. Med. (2007).

53. Burstein, S. PPAR-gamma: a nuclear receptor with affinity for cannabinoids. Life Sci. 77, 1674-1684 (2005).

54. Kimura, T., Ohta, T., Watanabe, K., Yoshimura, H. & Yamamoto, I. Anandamide, an endogenous cannabinoid receptor ligand, also interacts with 5-hydroxytryptamine (5-HT) receptor. Biol Pharm Bull 21, 224-226 (1998).

55. Vigano, D., Rubino, T. & Parolaro, D. Molecular and cellular basis of cannabinoid and opioid interactions. Pharmacol Biochem Behav 81, 360-368 (2005).

56. Solinas, M. et al. Nicotinic facilitation of delta-9-tetrahydrocannabinol (THC) discrimination involves endogenous anandamide. J Pharmacol Exp Ther S (2007).

57. Oz, M. Receptor-independent actions of cannabinoids on cell membranes: Focus on endocannabinoids. Pharmacol. Ther. 111, 114-144 (2006).

58. Melamede, R. J. Endocannabinoids: Multi-scaled, Global Homeostatic Regulators of Cells and Society. 601, (2006).

59. Datwyler, S. L. & Weiblen, G. D. Genetic variation in hemp and marijuana (Cannabis sativa L.) according to amplified fragment length polymorphisms. J Forensic Sci 51, 371-375 (2006).

60. Russo, E. B. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett 25, 31-39 (2004).

61. Prigogine, I. From Being to Becoming: Time and Complexity in the Physical Sciences (W H Freeman & Co (Sd), 1981).

62. Melamede, R. J. Dissipative Structures and the Origins of Life. 601, (2006).

63. Nicolis, G. & Prigogine, I. Exploring Complexity: An Introduction (W.H. Freeman & Company, 1989).64. Beckman, K. B. & Ames, B. N. The free radical theory of aging matures. Physiol. Rev. 78, 547-581 (1998).

65. Balaban, R. S., Nemoto, S. & Finkel, T. Mitochondria, oxidants, and aging. Cell 120, 483-495 (2005).

66. NIH. NTP Toxicology and Carcinogenesis Studies of 1-Trans-Delta(9)- Tetrahydrocannabinol (CAS No. 1972-08-3) in F344 Rats and B6C3F1 Mice (Gavage Studies). Natl Toxicol Program Tech Rep Ser S 446, 1-317 (1996).

67. Chan, P. C., Sills, R. C., Braun, A. G., Haseman, J. K. & Bucher, J. R. Toxicity and carcinogenicity of delta 9-tetrahydrocannabinol in Fischer rats and B6C3F1 mice. Fundam Appl Toxicol 30, 109-117 (1996).

68. Zimmer, A., Zimmer, A. M., Hohmann, A. G., Herkenham, M. & Bonner, T. I. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc. Natl. Acad. Sci. U S A 96, 5780-5785 (1999).

69. Hampson, A. J., Grimaldi, M., Axelrod, J. & Wink, D. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. U S A 95, 8268-8273 (1998).

70. Bobrov, M. Y. et al. Antioxidant and neuroprotective properties of Narachidonoyldopamine. Neurosci. Lett. 431, 6-11 (2008).

71. Sheng, W. S. et al. Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia 49, 211-21 (2005).

72. Beckman, K. B. & Ames, B. N. Mitochondrial aging: open questions. Ann. N. Y. Acad. Sci. 854, 118-127 (1998).

73. McPartland, J. M. & Pruitt, P. L. Sourcing the Code:Searching for the Evolutionary Origins of Cannabinoid Receptors, Vanilloid Receptors, and Anandamide. Journal of Cannabis Therapeutics volume 2, Number 1, (2002).

74. Izzo, A. A. & Coutts, A. A. Cannabinoids and the digestive tract. Handb Exp Pharmacol 573-598 (2005).

75. Di Marzo, V. et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410, 822-825 (2001).

76. Williams, C. M. & Kirkham, T. C. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 143, 315-317 (1999).

77. Duncan, M., Davison, J. S. & Sharkey, K. A. Review article: endocannabinoids and their receptors in the enteric nervous system. Aliment Pharmacol Ther 22, 667-683 (2005).

78. Soderstrom, K., Tian, Q., Valenti, M. & Di Marzo, V. Endocannabinoids link feeding state and auditory perception-related gene expression. J. Neurosci. 24, 10013-10021 (2004).

79. Fride, E. et al. Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. Eur. J. Pharmacol. 419, 207-214 (2001).

80. Pi-Sunyer, F. X., Aronne, L. J., Heshmati, H. M., Devin, J. & Rosenstock, J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295, 761-775 (2006).

81. Kakafika, A. I., Mikhailidis, D. P., Karagiannis, A. & Athyros, V. G. The Role of Endocannabinoid System Blockade in the Treatment of the Metabolic Syndrome. J Clin Pharmacol S (2007).

82. van Oosten, B. W., Killestein, J., Mathus-Vliegen, E. M. & Polman, C. H. Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist. Mult. Scler. 10, 330-331 (2004).

83. Partosoedarso, E. R., Abrahams, T. P., Scullion, R. T., Moerschbaecher, J. M. & Hornby, P. J. Cannabinoid1 receptor in the dorsal vagal complex modulates lower oesophageal sphincter relaxation in ferrets. J. Physiol. 550, 149-158 (2003).

84. Atherton, J. C. The pathogenesis of Helicobacter pylori-induced gastro-duodenal diseases. Annu Rev Pathol 1, 63-96 (2006).

85. Sanger, G. J. Endocannabinoids and the gastrointestinal tract: what are the key questions? Br. J. Pharmacol. (2007).

86. Germano, M. P. et al. Cannabinoid CB1-mediated inhibition of stress-induced gastric ulcers in rats. Naunyn Schmiedebergs Arch Pharmacol 363, 241-244 (2001).

87. Massa, F. et al. The endogenous cannabinoid system protects against colonic inflammation. J. Clin. Invest. 113, 1202-1209 (2004).

88. Di Marzo, V. & Izzo, A. A. Endocannabinoid overactivity and intestinal inflammation. Gut 55, 1373-1376 (2006).

89. Pertwee, R. G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther. 74, 129-180 (1997).

90. Varma, N., Carlson, G. C., Ledent, C. & Alger, B. E. Metabotropic glutamate receptors drive the endocannabinoid system in hippocampus. J. Neurosci. 21, RC188 (2001).

91. Fowler, C. J. & Jacobsson, S. O. Cellular transport of anandamide, 2- arachidonoylglycerol and palmitoylethanolamide–targets for drug development? Prostaglandins Leukot Essent Fatty Acids 66, 193-200 (2002).

92. Maccarrone, M. et al. Anandamide hydrolysis by human cells in culture and brain. J. Biol. Chem. 273, 32332-32339 (1998).

93. Goparaju, S. K., Ueda, N., Taniguchi, K. & Yamamoto, S. Enzymes of porcine brain hydrolyzing 2-arachidonoylglycerol, an endogenous ligand of cannabinoid receptors. Biochem. Pharmacol. 57, 417-423 (1999).

94. Howlett, A. C., Mukhopadhyay, S. & Norford, D. C. Endocannabinoids and reactive nitrogen and oxygen species in neuropathologies. J Neuroimmune Pharmacol 1, 305-316 (2006).

95. Shoemaker, J. L., Seely, K. A., Reed, R. L., Crow, J. P. & Prather, P. L. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem (2007).

96. Bisogno, T., Martire, A., Petrosino, S., Popoli, P. & Di Marzo, V. Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington’s disease. Neurochem Int (2007).

97. Campbell, V. A. & Gowran, A. Alzheimer’s disease; taking the edge off with cannabinoids? Br. J. Pharmacol. (2007).

98. Monory, K. et al. The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 51, 455-466 (2006).

99. Panikashvili, D. et al. The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol Dis 22, 257-264 (2006).

100. Jin, K. L., Mao, X. O., Goldsmith, P. C. & Greenberg, D. A. CB1 cannabinoid receptor induction in experimental stroke. Ann. Neurol. 48, 257-261 (2000).

101. Sang, N., Zhang, J. & Chen, C. COX-2 oxidative metabolite of endocannabinoid 2- AG enhances excitatory glutamatergic synaptic transmission and induces neurotoxicity. J. Neurochem. 102, 1966-1977 (2007).

102. Varvel, S. A. & Lichtman, A. H. Evaluation of CB1 receptor knockout mice in the Morris water maze. J Pharmacol Exp Ther 301, 915-924 (2002).

103. Mbvundula, E. C., Bunning, R. A. & Rainsford, K. D. Arthritis and cannabinoids: HU-210 and Win-55,212-2 prevent IL-1alpha-induced matrix degradation in bovine articular chondrocytes in-vitro. J. Pharm. Pharmacol. 58, 351-358 (2006).

104. Massa, F. & Monory, K. Endocannabinoids and the gastrointestinal tract. J. Endocrinol. Invest. 29, 47-57 (2006).

105. Zozulinska, D. & Wierusz-Wysocka, B. Type 2 diabetes mellitus as inflammatory disease. Diabetes Res Clin Pract (2006).

106. Toyoda, K. et al. Protein-bound 4-hydroxy-2-nonenal: An endogenous triggering antigen of anti-DNA response. J. Biol. Chem. (2007).

107. Centonze, D., Finazzi-Agro, A., Bernardi, G. & Maccarrone, M. The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol Sci 28, 180-187 (2007).

108. Melamede, R. Indications for Cannabinoids: Autoimmune Diseases (Haworth Press, 2002).

109. Hill, M. N. & Gorzalka, B. B. Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression? Behav. Pharmacol. 16, 333-352 (2005).

110. Shohami, E. & Mechoulam, R. Multiple sclerosis may disrupt endocannabinoid brain protection mechanism. Proc. Natl. Acad. Sci. U S A 103, 6087-6088 (2006).

111. Sarchielli, P. et al. Endocannabinoids in Chronic Migraine: CSF Findings Suggest a System Failure. Neuropsychopharmacology 32, 1432 (2007).

112. Steffens, S. et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 434, 782-786 (2005).

113. Di Filippo, C., Rossi, F., Rossi, S. & D’Amico, M. Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN. J. Leukoc. Biol. 75, 453-459 (2004).

114. Lamontagne, D., Lepicier, P., Lagneux, C. & Bouchard, J. F. The endogenous cardiac cannabinoid system: a new protective mechanism against myocardial ischemia. Arch Mal Coeur Vaiss 99, 242-246 (2006).

115. Grainger, J. & Boachie-Ansah, G. Anandamide-induced relaxation of sheep coronary arteries: the role of the vascular endothelium, arachidonic acid metabolites and potassium channels. Br. J. Pharmacol. 134, 1003-1012 (2001).

116. Wagner, J. A., Varga, K., Jarai, Z. & Kunos, G. Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension 33, 429-434 (1999).

117. Deutsch, D. G. et al. Production and physiological actions of anandamide in the vasculature of the rat kidney. J. Clin. Invest. 100, 1538-1546 (1997).

118. Batkai, S. et al. Endocannabinoids Acting at CB1 Receptors Mediate the Cardiac Contractile Dysfunction in vivo in Cirrhotic Rats. Am J Physiol Heart Circ Physiol (2007).

119. Wagner, J. A. et al. Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature 390, 518-521 (1997).

120. Roberts, J. D., Gennings, C. & Shih, M. Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. Eur. J. Pharmacol. 530, 54-58 (2006).

121. Smith, P. A., Selley, D. E., Sim-Selley, L. J. & Welch, S. P. Low dose combination of morphine and Delta(9)-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors. Eur. J. Pharmacol. 571, 129- 137 (2007).

122. McCarberg, B. H. & Barkin, R. L. The Future of Cannabinoids as Analgesic Agents: A Pharmacologic, Pharmacokinetic, and Pharmacodynamic Overview. Am J Ther 14, 475-483 (2007).

123. Morphine stimulates vascular endothelial growth factor-like signaling in mouse retinal endothelial cells. Curr Neurovasc Res 3, 171-180 (2006).

124. Preet, A., Ganju, R. K. & Groopman, J. E. Delta(9)-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Oncogene (2007).

125. Blazquez, C. et al. Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res. 64, 5617-5623 (2004).

126. Grimaldi, C. et al. Anandamide inhibits adhesion and migration of breast cancer cells. Exp Cell Res 312, 363-373 (2006).

127. Sharkey, K. A. et al. Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. Eur J Neurosci (2007).

128. McLaughlin, R. J., Hill, M. N., Morrish, A. C. & Gorzalka, B. B. Local enhancement of cannabinoid CB1 receptor signalling in the dorsal hippocampus elicits an antidepressant-like effect. Behav. Pharmacol. 18, 431-438 (2007).

129. McKallip, R. J., Nagarkatti, M. & Nagarkatti, P. S. Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J. Immunol. 174, 3281-3289 (2005).

130. Portella, G. et al. Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J. 17, 1771-1773 (2003).

131. White, A. C., Munson, J. A., Munson, A. E. & Carchman, R. A. Effects of delta9-tetrahydrocannabinol in Lewis lung adenocarcinoma cells in tissue culture. J. Natl. Cancer Inst. 56, 655-658 (1976).

132. Casanova, M. L. et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J. Clin. Invest. 111, 43-50 (2003).

133. Jacobsson, S. O., Wallin, T. & Fowler, C. J. Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J Pharmacol Exp Ther 299, 951-959 (2001).

134. De Petrocellis, L. et al. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc. Natl. Acad. Sci. U S A 95, 8375-8380 (1998).

135. Sarfaraz, S., Afaq, F., Adhami, V. M., Malik, A. & Mukhtar, H. Cannabinoid receptor agonist induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest. J. Biol. Chem. (2006).

136. Flygare, J., Gustafsson, K., Kimby, E., Christensson, B. & Sander, B. Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma. FEBS Lett. 579, 6885-6889 (2005).

137. Jia, W. et al. Delta}9-Tetrahydrocannabinol-Induced Apoptosis in Jurkat Leukemia T Cells Is Regulated by Translocation of Bad to Mitochondria. Mol Cancer Res 4, 549-562 (2006).

138. Blazquez, C. et al. Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J. (2006).

139. Matias, I. & Di Marzo, V. Endocannabinoids and the control of energy balance. Trends Endocrinol Metab S 18, 27-37 (2007).

140. Goldbeter, A. Biological rhythms as temporal dissipative structures. Adv Chem Phys 135, 253-295 (2007).

141. Ottani, A., Leone, S., Sandrini, M., Ferrari, A. & Bertolini, A. The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors. Eur. J. Pharmacol. 531, 280-281 (2006).

142. Patel, S. et al. The general anesthetic propofol increases brain Narachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. Br. J. Pharmacol. 139, 1005-1013 (2003).

143. McPartland, J. M. et al. Cannabimimetic effects of osteopathic manipulative treatment. J Am Osteopath Assoc 105, 283-291 (2005).

144. Rousseaux, C. et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat. Med. 13, 35-37 (2007).

145. Wenger, T. & Moldrich, G. The role of endocannabinoids in the hypothalamic regulation of visceral function. Prostaglandins Leukot Essent Fatty Acids 66, 301-307 (2002).

 


 

Cannabis Science™ http://www.cannabisscience.com/

RESEARCH & DEVELOPMENT OVERVIEW http://www.cannabisscience.com/research-a-development.html

Share this page